Stay updated on Cabozantinib And Androgen Ablation in Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib And Androgen Ablation in Prostate Cancer Clinical Trial page.

Latest updates to the Cabozantinib And Androgen Ablation in Prostate Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe clinical trial record for cabozantinib with androgen ablation in metastatic prostate cancer is now displayed, with study details such as eligibility criteria, treatment plan, outcome measures, and a study protocol document. Previously, the page showed a 403 Forbidden error.SummaryDifference48%

- Check17 days agoChange DetectedThe footer now identifies the site as revision v3.8.0 instead of v3.7.2. The study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check31 days agoChange DetectedA banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence,” and the site revision changes from v3.7.1 to v3.7.2. The study page continues to display a 403 error.SummaryDifference1%

- Check38 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1 on the page displaying a 403 error.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now displays a 403 Forbidden error page with an added 403 HTML header and a Home link. This change replaces the previously visible study-record content and removes institution-specific references.SummaryDifference18%

- Check66 days agoChange DetectedFooter revision label updated to v3.7.0 from v3.6.6, indicating a page version upgrade. This change is limited to the site’s versioning text and does not affect study details or user actions.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib And Androgen Ablation in Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib And Androgen Ablation in Prostate Cancer Clinical Trial page.